Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Insights - The company achieved significant revenue growth in 2025, with total revenue reaching 716 million yuan, a year-on-year increase of 67.31%. The sales revenue from the product Sipulizumab was approximately 315 million yuan, representing a 633% increase from 2024 [4][5] - The company is expected to continue its revenue growth trajectory, with projected revenues of 2.458 billion yuan in 2026, 1.624 billion yuan in 2027, and 2.224 billion yuan in 2028 [4][7] - Sipulizumab has been included in China's National Medical Insurance Drug List, enhancing its affordability and accessibility, and the company is actively expanding its product pipeline with next-generation dual antibodies [5][6] Financial Summary - The company reported a net loss of 523 million yuan in 2025, but adjusted net profit (excluding share-based payment impacts) was -495 million yuan [4] - The gross margin for 2025 was 87.7%, with a projected gross margin of 95% for the following years [7][10] - The price-to-sales (P/S) ratio is projected to be 7.4, 11.2, and 8.2 for 2026, 2027, and 2028 respectively, indicating a favorable valuation compared to historical performance [4][7]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1][15] Core Insights - The company achieved total revenue of 13.042 billion HKD in 2025, representing a year-on-year growth of 38.4%. Product sales revenue reached 11.896 billion HKD, up 44.6% year-on-year. The company reported a net profit of 814 million HKD under IFRS, compared to a loss of 95 million HKD in 2024, and a Non-IFRS net profit of 1.723 billion HKD. This growth is attributed to the leading position in oncology products and rapid expansion in cardiovascular and metabolic product lines. The company has also entered a global strategic collaboration with Takeda Pharmaceutical, which will gradually confirm high upfront payments in the coming years. The profit forecasts for 2026-2027 have been raised, with expected net profits of 2.178 billion HKD, 2.504 billion HKD, and 2.960 billion HKD for 2026, 2027, and 2028 respectively, leading to a current price-to-earnings ratio of 77.0, 67.0, and 56.6 times [6][10]. Financial Summary - The company’s total revenue is projected to reach 18.515 billion HKD in 2026, with a year-on-year growth of 42.0%. The net profit is expected to increase to 2.178 billion HKD, reflecting a growth of 167.7% compared to 2025. The gross margin is anticipated to be 86.8%, and the net margin is expected to be 11.8% [10][12]. Global Expansion and Innovation - The company is accelerating its global layout, with multiple innovative pipelines entering global MRCT. The core product IBI363 has initiated a global MRCT Phase III clinical study for IO-resistant squamous NSCLC. IBI343 has received two BTD designations from NMPA and FTD from the FDA, with its first international Phase III study for third-line gastric cancer ongoing in China and Japan. IBI324 is expected to start an international Phase III clinical study in 2026 [7][8]. Future Product Pipeline - The next-generation pipeline focuses on oncology with IO+ADC technologies, including IBI363, IBI343, IBI3003, bispecific ADCs, and dual payload ADCs. These aim to enhance treatment standards or address unmet needs in various fields. Several pipelines are currently in international Phase I clinical studies [8]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Insights - The company achieved total revenue of 111.905 billion yuan in 2025, representing a year-on-year growth of 1.87%. However, the net profit attributable to shareholders decreased by 1.39% to 5.904 billion yuan [8] - The profit structure continues to improve, with a decrease in the gross profit margin from the connection business and an increase in the gross profit margin from the comprehensive energy and smart home segments [8] - The privatization pricing reflects a significant revaluation potential, with a transaction value of 599.24 billion HKD, corresponding to a 12 times PE based on the company's core profit for 2024 [8] Financial Performance Summary - Total revenue forecast for 2024A is 109.853 billion yuan, with a projected increase to 120.436 billion yuan by 2028E, reflecting a compound annual growth rate (CAGR) of approximately 2.74% [1] - The net profit attributable to shareholders is expected to rise from 5.904 billion yuan in 2025A to 7.486 billion yuan by 2028E, indicating a growth rate of 4.89% [1] - The latest diluted EPS is projected to increase from 5.22 yuan in 2025A to 6.61 yuan in 2028E, with a corresponding decrease in the P/E ratio from 10.68 to 8.42 [1]

Investment Rating - The investment rating for the company is "Buy" (maintained) [5] Core Views - The company achieved stable performance in 2025, with total revenue of 7.224 billion yuan, a year-on-year increase of 15.3%, and a net profit attributable to shareholders of 1.425 billion yuan, up 33.4% [5] - The growth in revenue was driven by the konjac product category, which led to a significant increase in the vegetable product segment, accounting for 62.4% of total revenue, up 8.6 percentage points year-on-year [6] - The company is focusing on product innovation and exploring overseas markets, with overseas revenue reaching 117 million yuan, a year-on-year increase of 48% [7] Financial Performance - In 2025, the company reported a gross margin of 48.0%, with a slight decrease of 0.1 percentage points year-on-year, while the net profit margin increased by 2.7 percentage points to 19.7% [7] - The company plans to distribute dividends totaling approximately 851 million yuan, corresponding to a payout ratio of 60% [5] - The forecast for net profit attributable to shareholders for 2026-2028 is 1.64 billion, 1.90 billion, and 2.14 billion yuan, with respective growth rates of 15.1%, 15.7%, and 12.9% [8]

Investment Rating - The report maintains a "Buy" rating for China Resources Gas (01193) [2][7] Core Views - The company reported a revenue of HKD 97.73 billion for 2025, a decrease of 4.81% year-on-year, with a net profit attributable to shareholders of HKD 3.547 billion, down 13.23% [7] - The company plans to distribute a final dividend of HKD 0.65 per share, maintaining an annual dividend of HKD 0.95, resulting in a dividend yield of 4.97% based on the closing price on March 30 [7] - Natural gas sales volume for 2025 is projected to be 401.8 billion cubic meters, with a slight increase of 0.7% year-on-year, and a gross margin of HKD 0.54 per cubic meter [7] - The company is actively enhancing its gas sourcing capabilities, with a significant increase in total gas volume to 6.1 billion cubic meters, up 52.2% year-on-year [7] - The company’s capital expenditure is expected to decrease by 16.9%, while free cash flow is projected to increase by 12.3% [7] Financial Data and Profit Forecast - Revenue projections for the years 2024 to 2028 are as follows: HKD 102.676 billion (2024), HKD 97.733 billion (2025), HKD 100.012 billion (2026E), HKD 102.589 billion (2027E), and HKD 105.066 billion (2028E) [6][8] - Net profit attributable to shareholders is forecasted to be HKD 4.088 billion (2024), HKD 3.547 billion (2025), HKD 4.315 billion (2026E), HKD 4.757 billion (2027E), and HKD 5.350 billion (2028E) [6][8] - The company’s earnings per share (EPS) is projected to be HKD 1.80 (2024), HKD 1.55 (2025), HKD 1.88 (2026E), HKD 2.08 (2027E), and HKD 2.34 (2028E) [6][8] - The price-to-earnings (P/E) ratios for 2026 to 2028 are estimated at 10.1, 9.2, and 8.2 respectively [7]

Investment Rating - The report maintains a "Buy" rating for Mixue Group [4][10][14] Core Insights - Mixue Group reported a revenue of RMB 33.6 billion for 2025, representing a year-on-year growth of 35%, and a net profit attributable to shareholders of RMB 5.9 billion, up 33% year-on-year, exceeding expectations due to higher-than-expected new store openings [10][11] - The company plans to slow down its store expansion in 2026, focusing on improving quality and efficiency, leading to a slight reduction in net profit forecasts for 2026 and 2027 [10][11] - The target price has been adjusted from HK$ 566 to HK$ 400 based on the DCF model [10][11] Financial Data and Profit Forecast - Revenue projections for Mixue Group are as follows: - 2024: RMB 24,829 million - 2025: RMB 33,560 million - 2026E: RMB 36,771 million - 2027E: RMB 41,128 million - 2028E: RMB 45,752 million - Net profit attributable to shareholders is projected as: - 2024: RMB 4,437 million - 2025: RMB 5,887 million - 2026E: RMB 6,170 million - 2027E: RMB 7,094 million - 2028E: RMB 8,070 million - The expected growth rates for revenue and net profit show a trend of high growth in the earlier years, with a gradual decline in growth rates in the later years [9][16]

Investment Rating - The investment rating for the company is maintained at "Buy" [1] Core Views - The company reported a revenue of 5.233 billion RMB for 2025, a year-on-year decrease of 13.8%, while the net profit attributable to shareholders was 58.2 million RMB, an increase of 4.3% year-on-year [1] - The company has proactively optimized its restaurant network by closing 189 underperforming or expiring lease stores, resulting in a total of 644 stores at the end of the year [1] - The company plans to distribute a final dividend of 0.02 HKD per share, with a payout ratio of 42.1%, and has committed to maintaining a payout ratio of no less than 40% in the future [1] - The company is shifting its strategy to focus on optimizing existing operations rather than aggressive expansion, expecting to see fundamental recovery as it streamlines its brand matrix and strengthens operational capabilities [1] Revenue and Profitability - The restaurant, takeaway, and merchandise sales revenues for 2025 were 3.976 billion RMB, 1.002 billion RMB, and 244 million RMB respectively, with year-on-year changes of -18.5%, -4.0%, and +74.7% [2] - The average daily sales for the main brands showed declines, with Taier, Song Hotpot, and Jiumaojiu experiencing year-on-year decreases of -11.5%, -16.5%, and -15.8% respectively [2] - The overall operating profit margin for the company was 12.3%, showing resilience despite the pressure on same-store sales [3] Cost Structure and Efficiency - The cost structure remained stable, with raw materials and consumables accounting for 35.5% of revenue, employee costs at 29.5%, and depreciation of right-of-use assets at 9.3% [3] - The company has improved its supply chain capabilities, leading to a slight decrease in the proportion of raw material costs [3] Strategic Adjustments - The company opened 26 new restaurants in 2025 while closing 189, adjusting its total store count to 644 [4] - The company is exploring new business opportunities, including the launch of a new brand "Chao Na Bian" and a strategic partnership with North American brand Big Way [4] Profit Forecast and Valuation - The net profit forecasts for 2026 and 2027 have been revised down to 183 million RMB and 249 million RMB, reflecting a decrease of 27.5% and 19.8% respectively [5] - The target price has been adjusted to 2.10 HKD, down from 3.52 HKD, corresponding to a 14x PE for 2026 [5]

Investment Rating - The investment rating for the company is maintained as "Buy" with a target price of HKD 3.39 [1][10]. Core Insights - The company reported a revenue of HKD 5.056 billion for 2025, a decrease of 2% year-on-year, and a net profit attributable to shareholders of HKD 632 million, down 58% year-on-year. The decline in performance was primarily due to a significant drop in the average price of premium coking coal, which fell by 36% due to market conditions and product structure adjustments. However, the company managed to reduce its unit production cost of raw coking coal by 13% through cost control measures and expanded its coal trading business, which contributed to new revenue streams. The high dividend payout ratio of 97% highlights the company's value proposition in terms of dividends [6][10]. Financial Performance Summary - For 2025, the company achieved a raw coking coal production of 5.25 million tons, a 6% increase year-on-year, benefiting from the completion of coal mine adjustments. The production of premium coking coal was 3.15 million tons, a slight decrease of 0.3% due to changes in coal quality and geological conditions. The company also initiated a coal trading business with a volume of 1.7 million tons, accounting for 35% of total revenue, effectively diversifying its income sources [7][8]. - The gross margin for 2025 was 21%, a decrease of 31 percentage points year-on-year. After excluding the impact of the coal trading business, the core business gross margin was 33%, reflecting a 19 percentage point decline, yet still demonstrating some resilience in profitability. The net profit attributable to shareholders fell by 58% to HKD 632 million, mainly due to a significant drop in selling prices that reduced gross profit by HKD 1.568 billion [8][9]. - The company plans to distribute a final dividend of HKD 0.06 per share, along with an interim dividend of HKD 0.06, totaling HKD 0.12 per share for the year, maintaining a high payout ratio of 97%, which provides stable returns to shareholders during the industry adjustment period [9][10]. Earnings Forecast and Valuation - The company has completed its product structure adjustment, and the coking coal market prices are expected to stabilize in 2026. The ongoing geopolitical tensions are likely to support coking coal prices indirectly. The company’s trading business exceeded previous expectations, leading to revised net profit estimates for 2026 and 2027 to HKD 970 million and HKD 1.05 billion, respectively. The target price has been adjusted to HKD 3.39, reflecting a slight decrease from the previous estimate of HKD 3.40, while maintaining the "Buy" rating [10].

Investment Rating - The report maintains a "Buy" rating for the company with a target price of HKD 1.90 [9][7]. Core Insights - The company's net profit for 2025 is projected to be RMB 9.77 billion, a decrease of 7.4% year-on-year. The insurance service performance is expected to decline by 49.3%, while investment performance is anticipated to rise by 18.8% [2]. - The company plans to increase its dividend per share (DPS) to RMB 0.07, a significant increase of 38% from the previous year, raising the payout ratio to 30% from 20% [2]. - The report indicates a mixed performance in the property reinsurance segment, with domestic business showing a combined ratio (COR) increase of 3.21 percentage points to 95.98%, while international business (including Bridge Re) shows a decrease of 3.52 percentage points to 81.19% [3]. - The life reinsurance segment is expected to see a 2.5% increase in insurance service revenue, but net profit is projected to decline by 7.4% to RMB 3.9 billion due to updated business assumptions and impairment provisions [4]. - The direct property insurance business is facing challenges, with a COR of 99.17%, up 1.50 percentage points, leading to a 14.7% decline in net profit to RMB 1.3 billion [5]. - The overall investment yield is expected to decrease, with net investment yield dropping by 0.27 percentage points to 3.69% and total investment yield down by 0.17 percentage points to 4.66% [6]. Summary by Sections Financial Performance - The company's gross premium income for 2025 is projected at RMB 103.09 billion, reflecting a growth of 1.7% [12]. - Total investment income is expected to be RMB 20.66 billion, a significant increase of 31.4% year-on-year [12]. - The report forecasts a decline in net profit for 2026 to RMB 9.31 billion, a decrease of 4.74% [12]. Valuation and Forecast - The report adjusts the EPS forecasts for 2026, 2027, and 2028 to RMB 0.22, 0.25, and 0.28 respectively, with a downward adjustment of 20% and 17% [7]. - The valuation is based on a discounted cash flow (DCF) method, maintaining the target price at HKD 1.90 [7][13].

Investment Rating - The report initiates coverage with a "Buy" rating for Jiangnan Buyi [5][9] Core Views - Jiangnan Buyi is a high-quality local designer brand group with a well-established multi-brand matrix, demonstrating resilient growth through design-driven strategies and fan economy [7][9] - The company has achieved historical highs in revenue and net profit, with FY25 revenue reaching 5.55 billion RMB, a year-on-year increase of 4.6%, and net profit of 890 million RMB, up 5.3% [7][18] - The report anticipates continued revenue growth of 7% for FY26 and FY27, and 6% for FY28, with net profit growth of 9% for FY26 and 7% for FY27 and FY28 [9][10] Summary by Sections 1. Local High-Quality Designer Brand Group - Jiangnan Buyi has been deeply engaged in the apparel industry for over 30 years, focusing on the design and sale of fashion clothing, shoes, accessories, and home products [17] - The company operates multiple brands, including mid-to-high-end women's brands JNBY and LESS, mid-to-high-end men's brand CROQUIS, and children's brand jnby by JNBY, among others [17][21] 2. Women's Apparel Industry Transition - The Chinese women's apparel market is transitioning from scale expansion to quality enhancement, with the market size expected to reach 1,059.2 billion RMB by 2025, growing approximately 1% year-on-year [48][51] - The high-end women's apparel segment is growing significantly faster than the mass market, driven by consumer demand for quality and personalized products [51][56] 3. Unique Design and Fan Economy - Jiangnan Buyi's competitive advantage lies in its design-driven approach, multi-brand development, and fan economy strategy, which collectively enhance brand loyalty and customer retention [63] - The company focuses on original design to attract middle-class consumers seeking unique aesthetics, supported by a strong membership program that has seen high-value members increase from 90,000 in FY16 to nearly 330,000 in FY25 [7][11][63] 4. Financial Performance and Profitability - Jiangnan Buyi's revenue has grown from 1.38 billion RMB in FY14 to 5.55 billion RMB in FY25, with an 11-year CAGR of 13%, and net profit has increased from 150 million RMB to 890 million RMB, with an 11-year CAGR of 18% [34] - The company maintains a stable gross margin of around 66%, with net profit margin at 16% in FY25, reflecting strong operational efficiency [39][46] 5. Earnings Forecast and Valuation - The report projects Jiangnan Buyi's revenue for FY26 to reach 5.96 billion RMB, with net profit expected to be 969 million RMB, reflecting a PE ratio of 14 times for FY26 [9][10] - The valuation considers comparable company metrics and accounts for the discount factors in the Hong Kong stock market [9]